Advancing neuroprotection and atherosclerosis prevention through familial hypercholesterolemia management: Analyzing comorbidity burden with stroke, coronary heart disease, hypertension, and diabetes.

ABSTRACT:

Background

Despite the World Health Organization's prioritization of familial hypercholesterolemia (FH), its global diagnostic rate remains critically low, leading to inadequate treatment and control, thereby increasing the risk of atherosclerotic cardiovascular disease. This study aimed to investigate the comorbidity burden of FH in China and analyze the differences between familial and general hypercholesterolemia (HC) populations.

Methods

Using a national medical insurance database from 2013 to 2017 including 13,976 patients with FH and 13,976 matched control patients with HC, we utilized case-control methods to compare the composition ratio, comorbidity rates, medical expenses, and healthcare burden of patients with FH to those of control patients.

Results

The FH

SUBMITTER: Wang J 

PROVIDER: S-EPMC12486938 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature